Why Is Enliven Therapeutics (NASDAQ:ELVN) Moving Back Into Focus?
Enliven Therapeutics (NASDAQ:ELVN) is gaining attention as selective risk appetite shifts towards smaller companies with clear milestones, financial transparency, and reliable customers. The key question for the company is whether its precision oncology medicines can ensure consistent execution and growth. While market trends provide context, the company's specific progress and disclosures are more critical for investors to evaluate its long-term potential.
Enliven Therapeutics Price Target Announced at $70.00/Share by Morgan Stanley
Morgan Stanley has set a price target of $70.00 per share for Enliven Therapeutics. This target provides investors with a specific valuation outlook from a major financial institution.
Enliven Therapeutics Initiated at Overweight by Morgan Stanley
Morgan Stanley has initiated coverage on Enliven Therapeutics with an "Overweight" rating. This indicates a positive outlook from the investment bank regarding the company's stock performance.
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
This article highlights five new analyst initiations for Friday, October 2, 2026. Notably, Morgan Stanley initiated coverage on Enliven Therapeutics with an Overweight rating and a $70 price target. Other companies receiving new coverage include Vylor, LB Pharmaceuticals, Sailpoint, and Avalyn Pharma, with ratings ranging from Outperform to Sector Weight.
Morgan Stanley initiates Enliven Therapeutics stock at overweight By Investing.com
Morgan Stanley has initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) with an overweight rating and a $70 price target, citing the company's strong cash position and promising clinical-stage oncology drug, ELVN-001. The stock is up 200% year-to-date, trading at $46.21, and is supported by positive analyst targets ranging from $64 to $82. Enliven Therapeutics is expected to initiate its pivotal Phase 3 ENABLE-2 trial in late 2026, with topline data anticipated in 2028-2029 and first revenues projected for 2030, with an estimated $2.6 billion in revenue by 2036.
Director Jeffrey Garland proposes selling 13,000 Enliven Therapeutics (NASDAQ: ELVN) shares.
Enliven Therapeutics director Jeffrey Garland has filed a Rule 144 notice proposing the sale of 13,000 common shares of ELVN, valued at approximately $606,719.10. The proposed sale, scheduled for October 1, 2026, through Morgan Stanley Smith Barney LLC, follows an equivalent stock option exercise. The company currently has 73,270,761 shares outstanding.
Enliven Therapeutics stock initiated at Overweight by JPMorgan
JPMorgan initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) with an Overweight rating and a $75.00 price target, implying a 64% upside. The investment thesis is centered on ELVN-001, a selective ATP-competitive BCR::ABL inhibitor, which is expected to be a key treatment for chronic-phase CML patients, especially those post-asciminib. Several other analysts, including William Blair, Barclays, and H.C. Wainwright, have also expressed positive outlooks on Enliven Therapeutics and ELVN-001.
ELVN Initiated Coverage by JP Morgan -- Rating Set to Overweight
JP Morgan has initiated coverage on Enliven Therapeutics (ELVN) with an "Overweight" rating and a price target of $75.00, suggesting significant upside. Despite this positive analyst sentiment, the company has a low GF Score™ of 33/100, indicating below-average performance relative to peers, and has seen substantial insider selling totaling $11.8 million in the last three months. Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on cancer treatment, and its lack of revenue and negative earnings make traditional valuation challenging.
Understanding the Setup: (ELVN) and Scalable Risk
This article analyzes Enliven Therapeutics Inc. (NASDAQ: ELVN), indicating divergent sentiment and choppy conditions with elevated downside risk. It provides AI-generated trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The piece suggests no clear price positioning signal and highlights that no additional long-term support signals remain.
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock By Investing.com
Enliven Therapeutics CFO Benjamin Hohl sold 6,018 shares of company stock worth over $303,000 on September 17, 2026, as part of a pre-arranged trading plan. The sales occurred at prices between $49.31 and $51.70 per share, following an exercise of options. Post-transaction, Hohl directly holds 38,000 shares and options for 181,018 additional shares, while the stock shows strong yearly returns but is considered overvalued by InvestingPro.
Enliven Therapeutics (ELVN) CFO exercises options, sells 6,018 shares
Enliven Therapeutics' CFO, Benjamin Hohl, exercised stock options for 3,982 shares at $14.85 each and subsequently sold 6,018 shares of common stock at weighted-average prices between $50.03 and $51.49 on September 17, 2026. These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 18, 2026. Following these actions, Hohl retains 181,018 stock options from the original grant and certain restricted stock units.
Enliven Therapeutics Insider Sold Shares Worth $251,754, According to a Recent SEC Filing
An insider at Enliven Therapeutics (ELVN) recently sold shares valued at $251,754, as disclosed in a recent SEC filing. The article, published on MarketScreener, highlights this transaction and provides additional context on the company's recent activities, including conference presentations and analyst ratings. Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for conditions like chronic myeloid leukemia and HER2-positive cancers.
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock
Benjamin Hohl, CFO of Enliven Therapeutics (NASDAQ:ELVN), sold 6,018 shares of company stock for $303,003 on September 17, 2026, as part of a Rule 10b5-1 trading plan. The sales occurred at prices between $49.31 and $51.70 per share, following an exercise of options to acquire 3,982 shares. Despite the stock being down 8.4% in the past week, it has seen a 145% return over the past year and has received several positive analyst ratings.
Enliven Therapeutics CFO Benjamin Hohl sells $303,003 in stock By Investing.com
Enliven Therapeutics CFO Benjamin Hohl sold 6,018 shares of the company's common stock for $303,003 through a Rule 10b5-1 trading plan. These sales occurred at prices ranging from $49.31 to $51.70 per share. Prior to these transactions, Hohl exercised options to acquire 3,982 shares, and he now directly holds 38,000 shares with options for an additional 181,018 shares.
Enliven Therapeutics CFO Completes Stock Option Exercise and Multi-Tranche Stock Sales
Benjamin Hohl, the Chief Financial Officer of Enliven Therapeutics, Inc. (NASDAQ:ELVN), recently exercised stock options for 3,982 shares at $14.85 per share and subsequently sold 6,018 shares in three separate transactions on September 17, 2026. These transactions, executed under a Rule 10b5-1 trading plan adopted in March 2026, resulted in weighted average sales prices ranging from $50.0286 to $51.4929. Following these activities, Hohl directly holds 38,000 shares and retains options for 181,018 shares.
Enliven Therapeutics Insider Sold Shares Worth $303,003, According to a Recent SEC Filing
Enliven Therapeutics' CFO, Benjamin Hohl, sold 6,018 shares of the company (ELVN) on September 17, 2026, for a total of $303,003. This transaction was disclosed in a recent SEC filing. Access to the full details of this report requires a premium subscription.
Enliven Therapeutics (ELVN) officer lines up new stock sale
An Enliven Therapeutics (ELVN) officer, Benjamin Hohl, plans to sell up to 12,036 shares of common stock, valued at approximately $591,208.32, through Jefferies LLC under a Rule 144 notice. These shares stem from previously exercised options in late 2024, and the proposed sale aligns with a Rule 10b5-1 selling plan adopted on March 18, 2026. The company currently has 73,000,000 shares outstanding.
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: Biotech Innovator with a 47% Upside Potential
Enliven Therapeutics, Inc. (ELVN) is a clinical-stage biopharmaceutical company focused on developing small molecule inhibitors for cancer, with two programs in Phase 1 trials targeting chronic myeloid leukemia and non-small cell lung cancer. Despite lacking current revenue, the company holds a market cap of $3.68 billion and is seen as a significant growth opportunity by analysts, who project an average 47.09% upside potential. Investors are advised to monitor clinical trial progress and regulatory milestones for future stock performance.
Transcript : Enliven Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 11
This article provides a transcript of Enliven Therapeutics, Inc.'s presentation at the Morgan Stanley 24th Annual Global Healthcare Conference on September 16, 2026, at 11:30 AM. It notes that the full transcript is reserved for subscribers, offering unlimited browsing and expert tools. The article also lists recent news regarding Enliven Therapeutics, including presentations of clinical trial data and analyst ratings.
Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Enliven Therapeutics will present data from its ENABLE Phase 1 clinical trial of ELVN-001 at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting. The presentations will include an oral session and a poster, detailing ELVN-001's efficacy as a selective ATP-competitive inhibitor for chronic myeloid leukemia (CML), especially against the T315I mutation. This meeting will be an encore presentation of data previously shared at the European Hematology Association (EHA) 2026 Congress.
Discipline and Rules-Based Execution in ELVN Response
This article provides an AI-generated analysis of Enliven Therapeutics Inc. (NASDAQ: ELVN), indicating a neutral near and mid-term outlook with a potentially positive long-term bias. It outlines various institutional trading strategies, including long, breakout, and short positions, based on different risk profiles and time horizons. The analysis also highlights specific support and resistance levels, emphasizing risk-reward ratios for potential trades.
Enliven Therapeutics Presents ELVN-001 Data at SOHO Annual Meeting
Enliven Therapeutics will present data from its ENABLE Phase 1 clinical trial for ELVN-001 at the SOHO Annual Meeting from September 9-12, 2026. The trial focuses on evaluating the safety and efficacy of ELVN-001, a highly selective small molecule kinase inhibitor, in chronic myeloid leukemia patients, particularly those with T315I mutations. This presentation aims to provide critical insights for future treatments and strengthen Enliven's position in precision medicine.
Handelsbanken Fonder AB Buys New Shares in Enliven Therapeutics, Inc. $ELVN
Handelsbanken Fonder AB acquired 17,300 shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) valued at approximately $878,000 during the second quarter. Institutional investors and hedge funds now collectively own 95.08% of the company's stock, while insider transactions show sales totaling $11.3 million over the past 90 days. Despite a recent earnings miss, analysts maintain a "Moderate Buy" rating with an average price target of $75.00 for ELVN.
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
William Blair initiated coverage on Enliven Therapeutics (NASDAQ: ELVN) with an Outperform rating, highlighting the potential of its lead drug candidate, ELVN-001, to transform chronic myeloid leukemia (CML) treatment. ELVN-001 has shown positive Phase 1 data, demonstrating significant major molecular response rates, and the company has a cash runway into 2030. Analysts believe ELVN-001 could disrupt the CML market due to its differentiated profile and effectiveness against resistance mutations to current market leaders.
Benjamin Hohl Sells 6,018 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock
Enliven Therapeutics CFO Benjamin Hohl sold 6,018 shares of ELVN stock on August 17th for over $352,000, reducing his direct ownership by 13.07%. This transaction was part of a pre-arranged trading plan, following similar sales in July and June. Despite the insider selling, analyst sentiment remains a "Moderate Buy" with an average price target of $75.00, though the company recently missed EPS expectations.
Enliven (NASDAQ: ELVN) CFO sells 6,018 shares in 10b5-1 plan
Enliven Therapeutics, Inc.'s CFO, Benjamin Hohl, sold a total of 6,018 shares of Common Stock in two open-market transactions on August 17, 2026, under a Rule 10b5-1 trading plan. The sales were executed at weighted average prices around $58-$59 per share. A portion of these securities were restricted stock units (RSUs), contingent on vesting conditions.
Enliven Therapeutics (ELVN) CMO exercises options, sells stock
Enliven Therapeutics' Chief Medical Officer, Helen Louise Collins, exercised options for 5,000 shares at $2.48 per share and subsequently sold all 5,000 shares in the open market for approximately $293,000. These transactions, conducted under a Rule 10b5-1 trading plan adopted in October 2025, involved two tranches of sales at weighted average prices of $58.3717 and $59.3465. Following these transactions, Collins directly holds 111,268 stock options and 25,000 common stock shares.
Enliven Therapeutics, Inc. /US/ Number of Employees 2026 | Employee Count & Headcount Data
Enliven Therapeutics, Inc. had 53 employees as of March 2026, representing a 52.3% growth since 2023 but a 7.8% decline year-over-year. The company, headquartered in Boulder, Colorado, is a Biotech and Healthcare Services firm with most of its workforce in North America and an average salary of $186,796. Enliven Therapeutics is not actively hiring, with zero job postings in 2026, a significant decline from previous years.
Barclays Initiates Enliven Therapeutics at Overweight With $78 Price Target
Barclays has initiated coverage on Enliven Therapeutics (NASDAQ: ELVN) with an Overweight rating and a price target of $78. This indicates a positive outlook from the investment bank on the biopharmaceutical company's future performance.
Enliven Therapeutics (NASDAQ:ELVN) Now Covered by Barclays
Barclays has initiated coverage on Enliven Therapeutics (NASDAQ:ELVN) with an "overweight" rating and a $78 price target, suggesting a potential upside of 31.03%. This comes amidst mixed analyst sentiment, with a consensus "Moderate Buy" rating and an average target price of $75. The company recently reported a quarterly loss of $0.49 per share, missing analyst expectations, and has seen significant insider selling while institutional investors have increased their holdings.
ENLIVEN THERAPEUTICS, INC. : WILLIAM BLAIR INITIATES COVERAGE WITH OUTPERFORM RATING
William Blair has initiated coverage of Enliven Therapeutics, Inc. (ELVN.O) with an Outperform rating. The report, sourced from Reuters, indicates a positive outlook from the investment firm for the pharmaceutical company.
261,344 Shares in Enliven Therapeutics, Inc. $ELVN Acquired by TimesSquare Capital Management LLC
TimesSquare Capital Management LLC has acquired 261,344 shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) for approximately $13.3 million, representing a 0.43% stake in the company. Institutional investors now collectively own 95.08% of ELVN. Despite a recent EPS miss, analyst sentiment remains positive with a "Moderate Buy" rating and an average price target of $72.67.
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Enliven Therapeutics (NASDAQ:ELVN) has received a "Moderate Buy" consensus rating from brokerages, with an average 12-month price target of $72.67. This comes despite the company reporting a wider-than-expected quarterly loss of $0.49 per share. Recent insider selling, including a director's $9.6 million sale, has also occurred, with insiders collectively selling over $10 million in shares last quarter.
Stifel Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $82
Stifel has reiterated its Buy rating on Enliven Therapeutics (ELVN.US) and maintained its target price at $82. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
Tema ETFs LLC Grows Stake in Enliven Therapeutics, Inc. $ELVN
Tema ETFs LLC significantly increased its stake in Enliven Therapeutics (NASDAQ:ELVN) by 41% in the second quarter, now owning 60,694 shares valued at $3.08 million. This comes as institutional investors hold a substantial 95.08% of the company's stock, despite the company missing quarterly earnings estimates. Analysts generally maintain a "Moderate Buy" rating for ELVN, though insiders have recently sold a considerable amount of stock.
Certain Common Stock of Enliven Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2026.
Certain common stock of Enliven Therapeutics, Inc. (ELVN) are under a 61-day lock-up agreement, preventing executive officers and directors from selling or disposing of shares and related securities. This lock-up period began on June 11, 2026, and will end on August 11, 2026. The restrictions are designed to prevent market volatility post-offering.
Janus Henderson Group PLC Sells 1,660,724 Shares of Enliven Therapeutics, Inc. $ELVN
Janus Henderson Group PLC significantly reduced its stake in Enliven Therapeutics (NASDAQ:ELVN) by selling 1.66 million shares, retaining only 11,000 shares. Despite this, institutional investors still hold about 95.1% of the stock. Insider selling, including substantial sales by directors, also occurred, even as analysts largely maintain a "Moderate Buy" consensus with an average price target of $72.67, despite the company missing its latest quarterly earnings estimates.
Assenagon Asset Management S.A. Makes New Investment in Enliven Therapeutics, Inc. $ELVN
Assenagon Asset Management S.A. has acquired a new stake in Enliven Therapeutics (NASDAQ:ELVN), purchasing 306,574 shares valued at approximately $15.56 million. Other institutional investors have also adjusted their holdings in ELVN, while company insiders have recently sold shares totaling over $10 million. Analysts have set an average "Moderate Buy" rating and a consensus price target of $72.67 for Enliven Therapeutics.
Certain Options of Enliven Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2026.
Certain options of Enliven Therapeutics, Inc. are under a lock-up agreement that will end on August 11, 2026. This agreement restricts executive officers and directors from selling or otherwise disposing of shares of common stock and related securities for 61 days, starting from June 11, 2026. The restrictions are designed to prevent market instability after a public offering.
Dimensional Fund Advisors LP Raises Holdings in Enliven Therapeutics, Inc. $ELVN
Dimensional Fund Advisors LP significantly increased its stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) by 70.9% in the first quarter, now holding 681,715 shares valued at $26.7 million. Other institutional investors also adjusted their holdings, contributing to 95.08% institutional ownership. Despite a quarterly loss and insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $70.50, following several price target increases.
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Maintains Target Price $70
LifeSci Capital has reiterated its Buy rating for Enliven Therapeutics (ELVN.US) and maintained its target price at $70. This indicates a continued positive outlook from the firm regarding the company's stock performance and potential.
LifeSci Capital Maintains Enliven Therapeutics(ELVN.US) With Buy Rating, Raises Target Price to $70
LifeSci Capital has reiterated its Buy rating for Enliven Therapeutics (ELVN.US) and increased its target price to $70. This updated target price indicates a strong positive outlook from the firm regarding the company's future performance.
A Quick Look at Today's Ratings for Enliven Therapeutics(ELVN.US), With a Forecast Between $68 to $82
This article provides a quick look at current analyst ratings for Enliven Therapeutics (ELVN.US), noting a forecast price range of $68 to $82. It summarizes that the company has received 1 Buy rating and 1 Strong Buy rating from analysts.
Enliven Therapeutics (ELVN) director exercises options, sells 158,795 shares
Enliven Therapeutics director Mika K. Derynck exercised stock options for 158,795 shares on August 4, 2026, at various exercise prices, then sold all 158,795 shares at a weighted average price of $60.2134 per share. These transactions were conducted as part of a Rule 10b5-1 trading plan adopted in April 2025, with all options being fully vested and exercisable. The total gross sale proceeds were approximately $9.56 million, resulting in an approximate pre-tax spread of $7.84 million.
Enliven Therapeutics director Mika Derynck sells $9.56m shares
Enliven Therapeutics director Mika Derynck sold 158,795 shares of company stock for approximately $9.
Enliven Therapeutics, Inc. Stock 12‑Month Price Target Raised to $70.9, Implies 19% Upside
Enliven Therapeutics, Inc. (ELVN) has seen its average 12-month price target raised from $65.8 to $70.9 by 10 analysts, suggesting a 19% potential upside from its Aug. 5 closing price. The consensus rating from 11 covering analysts remains a "Buy," with no hold or sell recommendations. Investors can find more detailed analyst data and historical recommendations on TradingView's Forecasts tab and News Flow.
ENLIVEN THERAPEUTICS, INC. : GUGGENHEIM CUTS TARGET PRICE TO $78 FROM $80
Guggenheim has reduced its target price for Enliven Therapeutics, Inc. (ELVN.O) from $80 to $78. This financial adjustment was reported by Reuters. The article itself is a brief news update, with no further details provided regarding the reasons for the target price cut.
FMR LLC and Abigail Johnson disclose 15% Enliven Therapeutics (ELVN) ownership
FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G/A, disclosing a 15.0% beneficial ownership stake in Enliven Therapeutics Inc. (ELVN). This ownership amounts to 10,713,540.41 shares of common stock, with FMR LLC holding sole voting power over 10,704,808 shares and both FMR LLC and Abigail Johnson having sole dispositive power over all reported shares. The filing indicates that this investment is for ordinary course of business purposes and not intended to influence control of the issuer.
ENLIVEN THERAPEUTICS, INC. : JEFFERIES RAISES TARGET PRICE TO $69 FROM $59
Jefferies has increased its target price for Enliven Therapeutics, Inc. (ELVN.O) to $69 from the previous $59. This adjustment indicates a positive outlook from the investment bank on the company's future performance. The article, sourced from Reuters, provides no further details on the rationale behind the price target change.
Guggenheim lowers Enliven Therapeutics stock price target to $78 By Investing.com
Guggenheim has reduced its price target for Enliven Therapeutics (NASDAQ:ELVN) to $78 from $80, while maintaining a Buy rating. This adjustment follows the company's second-quarter 2026 results and an update on ELVN-001, which received FDA Fast Track Designation and is expected to begin Phase 3 trials in the second half of the year. Despite the stock's significant year-to-date surge of 288%, InvestingPro analysis indicates it may be overvalued, though the company holds more cash than debt.
